Supporting data for “Development and characterisation of dry powder formulations of biopharmaceuticals for inhalation delivery"

Spray-dried and spray-freeze-dried powder formulations of monoclonal antibodies for severe asthma and COVID-19, and vaccines against SARS-COV-2 were characterised using differential scanning calorimetry, laser diffraction, scanning electron microscopy, and thermogravimetric analysis. The aerodynamic properties were determined using a Next Generation Impactor. The concentrations of the formulation components were quantified using high-performance liquid chromatography, Bradford protein assay, and UV absorbance. The stability of the dehydrated proteins was assessed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and size-exclusion chromatography. The biological activity of the monoclonal antibody was investigated using enzyme-linked immunosorbent assay and cell proliferation assays.